Eli Lilly has followed Novo Nordisk in announcing ... with investment projects ongoing in North Carolina and Indiana in the US. The new facility in Germany is preparing for the future, however ...

Eli Lilly and Company reported strong ... In May, we announced plans to invest an additional $5.3 billion in our Lebanon, Indiana manufacturing sites, bringing our total investment there to ...

It may not be too late to invest in Eli Lilly stock Eli Lilly's stock is undoubtedly expensive. But it trades at a high premium because it has the best weight loss drug in the market right now.

Eli Lilly has opened a $700 million R&D ... hosting Gateway Labs to the East Coast for the first time. Lilly disclosed plans to invest $700 million to set up a site in the Boston Seaport in ...

Novo Nordisk and Eli Lilly dominate it today ... The Motley Fool has a disclosure policy. Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The ...

Eli Lilly is selling bonds to fund the acquisition of drug developer Morphic. The sale is reportedly worth $5 billion. The company's stock was upgraded by Deutsche Bank analysts following its ...

A tablet, pen, and pad of paper on top of a financial report Eli Lilly has reported strong earnings growth. But as it grows, the market is now focused to the question whether the stock is ...

Pragada explains just how complicated Lilly's GLP-1 facilities are. He makes it clear that these projects are not simply up for grabs and available for a variety of builders to bid on. Since ...

Right now, there are a few reasons to believe that Eli Lilly has the upper hand in this competitive clash. Those reasons support buying its stock, assuming you don't want to invest in both companies.

Eli Lilly is announcing a new way to get its popular Zepbound drug. People who are in need of weight loss medications but do not have insurance coverage will soon have a new way to access one of ...

On Tuesday, Eli Lilly unveiled a towering 346,000-square-foot laboratory in Boston’s Seaport District, a building that will house 500 of the company’s scientists — 300 of whom are still to ...

Eli Lilly garnered widespread praise Tuesday for launching discounted versions of its blockbuster obesity drug Zepbound. Before, the treatment had only been sold in injectable pens for a list ...